Patents Assigned to GenPharm International
-
Publication number: 20130039850Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention is also directed to methods for producing human sequence antibodies.Type: ApplicationFiled: July 9, 2012Publication date: February 14, 2013Applicant: GENPHARM INTERNATIONAL, INC.Inventors: Nils LONBERG, Robert M. KAY, Dianne M. FISHWILD
-
Patent number: 8293480Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.Type: GrantFiled: September 26, 2008Date of Patent: October 23, 2012Assignee: Genpharm InternationalInventors: Nils Lonberg, Robert M. Kay
-
Patent number: 8231877Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens , such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.Type: GrantFiled: April 29, 2010Date of Patent: July 31, 2012Assignee: GenPharm International, Inc.Inventors: Nils Lonberg, Robert M. Kay, Dianne M. Fishwild
-
Patent number: 7722873Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.Type: GrantFiled: February 8, 2006Date of Patent: May 25, 2010Assignee: Genpharm International, Inc.Inventors: Nils Lonberg, Robert M. Kay, Dianne M. Fishwild
-
Patent number: 7084260Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.Type: GrantFiled: October 10, 1996Date of Patent: August 1, 2006Assignee: GenPharm International, Inc.Inventors: Nils Lonberg, Robert M. Kay, Dianne M. Fishwild
-
Patent number: 7041871Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.Type: GrantFiled: November 28, 2000Date of Patent: May 9, 2006Assignee: GenPharm International, Inc.Inventors: Nils Lonberg, Robert M. Kay
-
Publication number: 20060026703Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.Type: ApplicationFiled: December 10, 2004Publication date: February 2, 2006Applicant: GenPharm International, Inc.Inventors: Nils Lonberg, Robert Kay
-
Publication number: 20060015949Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.Type: ApplicationFiled: December 10, 2004Publication date: January 19, 2006Applicant: GenPharm International, Inc.Inventors: Nils Lonberg, Robert Kay
-
Publication number: 20060015957Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.Type: ApplicationFiled: December 10, 2004Publication date: January 19, 2006Applicant: GenPharm International, Inc.Inventors: Nils Lonberg, Robert Kay
-
Patent number: 6794132Abstract: The invention uses the power of display selection methods to screen libraries of human immunoglobulin genes from nonhuman transgenic animals expresing human immunoglobulins. Such screening produces unlimited numbers of high affinity human antibodies to any target of interest.Type: GrantFiled: December 1, 1999Date of Patent: September 21, 2004Assignees: Biosite, Inc., GenPharm International, Inc.Inventors: Joe Buechler, Gunars Valkirs, Jeff Gray, Nils Lonberg
-
Publication number: 20040107452Abstract: The present invention provides novel methods for modifying the genome of an animal cell which typically comprise the steps of: constructing a DNA molecule in which desired sequence modifications are contained in a segment of DNA (a “targeting DNA”) that is substantially isogenic with a DNA in the cell genome (a “target DNA”); introducing the targeting DNA construct into the cell (e.g., by microinjection, electroporation, transfection, or calcium phosphate precipitation); and selecting cells in which the desired sequence modifications have been introduced into the genome via homologous recombination.Type: ApplicationFiled: November 24, 2003Publication date: June 3, 2004Applicant: GENPHARM INTERNATIONAL, INC.Inventors: Anton Berns, Els Robanus Maandag, Hein Te Riele
-
Patent number: 6653113Abstract: The present invention provides novel methods for modifying the genome of an animal cell which typically comprise the steps of: constructing a DNA molecule in which desired sequence modifications are contained in a segment of DNA (a “targeting DNA”) that is substantially isogenic with a DNA in the cell genome (a “target DNA”); introducing the targeting DNA construct into the cell (e.g., by microinjection, electroporation, transfection, or calcium phosphate precipitation); and selecting cells in which the desired sequence modifications have been introduced into the genome via homologous recombination.Type: GrantFiled: February 19, 1999Date of Patent: November 25, 2003Assignee: Genpharm International, Inc.Inventors: Anton Berns, Els Robanus Maandag, Hein te Riele
-
Patent number: 6384298Abstract: Transgenic mice having a phenotype characterized by the substantial depletion of a mature lymphocytic cell type otherwise naturally occurring in the species from which the transgenic mouse is derived. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the lymphocytic cell type which is depleted. The transgene comprises a DNA sequence encoding a lymphatic polypeptide variant which inhibits maturation of the lymphocytic cell type.Type: GrantFiled: July 24, 1997Date of Patent: May 7, 2002Assignee: Genpharm InternationalInventors: Paulus Jacobus Angelinus Krimpenfort, Antonius Jozef Maria Berns
-
Patent number: 6300129Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.Type: GrantFiled: December 2, 1996Date of Patent: October 9, 2001Assignee: GenPharm InternationalInventors: Nils Lonberg, Robert M. Kay
-
Patent number: 6255458Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.Type: GrantFiled: March 13, 1998Date of Patent: July 3, 2001Assignee: GenPharm InternationalInventors: Nils Lonberg, Robert M. Kay
-
Patent number: 6023010Abstract: Transgenic mice having a phenotype characterized by the substantial depletion of a mature lymphocytic cell type otherwise naturally occurring in the species from which the transgenic mouse is derived. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the lymphocytic cell type which is depleted. The transgene comprised is a DNA sequence encoding a lymphatic polypeptide variant which inhibits maturation of the lymphocytic cell type.Type: GrantFiled: December 5, 1996Date of Patent: February 8, 2000Assignee: GenPharm InternationalInventors: Paulus Jacobus Angelinus Krimpenfort, Antonius Johannes Maria Berns
-
Patent number: 5877397Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g.Type: GrantFiled: September 19, 1994Date of Patent: March 2, 1999Assignee: GenPharm International Inc.Inventors: Nils Lonberg, Robert M. Kay
-
Patent number: 5874299Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies, i.e., antibodies encoded by immunoglobulin heavy and light chain genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, transgenes encoding unrearranged heterologous human immunoglobulin heavy and light chains are introduced into a non-human animal thereby forming a transgenic animal capable of producing antibodies encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody.Type: GrantFiled: February 14, 1997Date of Patent: February 23, 1999Assignee: GenPharm International, Inc.Inventors: Nils Lonberg, Robert M. Kay
-
Patent number: 5814318Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g.Type: GrantFiled: July 22, 1993Date of Patent: September 29, 1998Assignee: GenPharm International Inc.Inventors: Nils Lonberg, Robert M. Kay
-
Patent number: 5789215Abstract: The present invention provides novel methods for modifying the genome of an animal cell which typically comprise the steps of: constructing a DNA molecule in which desired sequence modifications are contained in a segment of DNA (a "targeting DNA") that is substantially isogenic with a DNA in the cell genome (a."target DNA"); introducing the targeting DNA construct into the cell (e.g., by microinjection, electroporation, transfection, or calcium phosphate precipitation); and selecting cells in which the desired sequence modifications have been introduced into the genome via homologous recombination.Type: GrantFiled: August 7, 1997Date of Patent: August 4, 1998Assignee: GenPharm InternationalInventors: Anton Berns, Els Robanus Maandag, Hein te Riele